Comments
Zydus Cadila has received the US health regulator’s nod to market mesalamine tablets used for the treatment of ulcerative colitis.
The USFDA has given its final approval to market mesalamine delayed-release tablets USP 1.2 g in the US market.
Zydus Cadila was the first to file an Abbreviated New Drug Application (ANDA) for the generic version of Lialda (mesalamine), the company said in a BSE filing today.
The company will manufacture the product at its Moraiya facility in Ahmedabad.
The Gujarat-based group has more than 115 approvals and has filed over 300 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.
Shares of Cadila Healthcare, the group’s listed entity, were trading at Rs 527.95 per scrip on BSE, up 7.66 per cent from its previous close.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.